Main > > >LIVER CANCER. *

---

Diagnostics. Differentiation of Hepato-
Cellular Carcinoma (HCC) from At-Risk & Normal Liver Parenchyma by Quantitative UltraSound Spectroscopy.
(*) Company; Patent & PR Web-Site Avai-
lable on Request.
UpDate: 2020. 01.05.




Embolization>Pressure Directed Arterial Embolization>By>Balloon Occlusion Microcatheters.
Designed for Procedures>
>TransArterial ChemoEmbolization (TACE)>
>HepatoCellular Carcinoma (HCC)
"Primary" Cancer
>Metastatic ColoRectal Cancer (mCRC)
>TransArterial RadioEmbolization (TARE)>
>Metastatic ColoRectal Cancer (mCRC)
EU Approval Date : 2018. 08.31.
USA Approval Date: 2018. 06.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.25.




HepatoCellular Carcinoma (HCC). Selec-
tive Internal RadioTherapy (SIRT).
Y-90 Glass Microspheres.
"Primary" Cancer.
TransArterial RadioEmbolisation (TARE).
CA Approval Year: 2002.
EU Approval Date: ?
HK Launch Date: ?
KR Launch Date: 2016. 01.26.
MY Launch Date: 2016. 10.19.
SG Launch Date: 2015. 06.11.
USA Approval : 1999.
(under Humanitarian Device Exemption).
(*) Company : BTG Intl.
Patent : Expired
TradeMark: TheraSphere.
Web-Site : www.btgplc.com
UpDate: 2018. 10.24.




HepatoCellular Carcinoma (HCC). TREAT.:
AtezolizuMAb+BevacizuMAb.
CN Approval Date: 2020. 10.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.26.




HepatoCellular Carcinoma (HCC). TREAT.:
Cabozantinib Tablets.
"Primary" Cancer.
>Previously Treated with Sorafenib.
CA Approval Date : 2019. 11.12.
EU Approval Date : 2018. 11.15.
JP Approval Date: 2020. 11.27.
USA Approval Date: 2019. 01.14.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.15.




HepatoCellular Carcinoma (HCC). TREAT.:
CryoAblation.
USA Approval Date: 2020. 01.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.10.




HepatoCellular Carcinoma (HCC). TREAT.:
Doxorubicin.HCl Eluting Embolic Bead.
(UK)
"Primary" Cancer.
TransArterial ChemoEmbolisation (TACE)
CA Approval Year: 2006.
CN Approval Date: 2014. 08.24.
EU Approval Year: 2003.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.23.




HepatoCellular Carcinoma (HCC). TREAT.:
Doxorubicin.HCl Eluting Embolic Bead.
(USA).
"Primary" Cancer.
TransArterial ChemoEmbolisation. (TACE).
EU Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.24.




HepatoCellular Carcinoma (HCC). TREAT.:
Doxorubicin.HCl Eluting Embolic Bead.
RadioOpaque.
"Primary" Cancer.
TransArterial ChemoEmbolisation (TACE)
Enabling Real-Time Visible, Lasting
Confirmation of Bead Location during &
Post-Embolisation
Visible Imaging>Computed Tomography.
>Cone-Beam Computed To-
mography
>Fluoroscopy.
CA Approval Date: 2016. 08.25.
CA Launch Date: 2016. 12.05.
EU Approval Date: 2017. 03.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.23.




HepatoCellular Carcinoma (HCC). TREAT.:
Doxorubicin.HCl Inj.
Delivery: Percutaneous Hepatic Perfusion
"Primary" Cancer.
EU Approval Date: 2012. 10.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.15.




HepatoCellular Carcinoma (HCC). TREAT.:
Embolization. Biodegradable 500 Emboli-
zation Microspheres Detectable by Ultra-
Sound.
"Primary" Cancer.
CA Approval Date : 2018. 11.21.
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




HepatoCellular Carcinoma (HCC). TREAT.:
Namodenoson. Small Orally Bioavailable Drug that binds with high affinity and selectivity to the A3 Adenosine Receptor (A3AR).
IL>Compassionate Use: 2019. 08.06.
IL>Rabin Medical Center
(*) Company: Can-Fite BioPharma Ltd.
UpDate: 2019. 11.24.




HepatoCellular Carcinoma (HCC). TREAT.:
NivoluMAb Inj. for IV Use.
Previously Treated with Sorafenib.
"Primary" Cancer.
USA Approval Date: 2017. 09.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.16.




HepatoCellular Carcinoma (HCC). TREAT.:
NivoluMAb+IpilimuMAb Inj. for IV Use.
Previously Treated with Sorafenib.
"Primary" Cancer.
USA Approval Date: 2020. 03.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.16.




HepatoCellular Carcinoma (HCC). TREAT.:
PembrolizuMAb Inj. 100 mg.
Previously Treated with Sorafenib.
"Primary" Cancer.
USA Approval Date: 2018. 11.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.13.




HepatoCellular Carcinoma (HCC). TREAT.:
RamuciruMAb Injection.
1st Line Treat. with Sorafenib.
2nd Line Treat. with RamuciruMAb.
Advanced or Metastatic Cancer.
Biomarker-Driven Therapy>Alpha-FetoPro>
>tein (AFP) of ≥400 ng/mL.
Mechanism: VEGFR2 Inhibition.
"Primary" Cancer.
USA Approval Date: 2019. 05.13.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.29.




HepatoCellular Carcinoma (HCC). TREAT.:
Regorafenib Tablets.
Previously Treated with Sorafenib.
Oral Multi Kinase Inhibition.
"Primary" Cancer.
USA Approval Date: 2017. 04.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.15.




HepatoCellular Carcinoma (HCC). UnRe-
sectable. TREAT.: Lenvatinib Capsules.
"Primary" Cancer.
CN Approval Date : 2018. 09.05.
EU Approval Date : 2018. 08.23.
JP Approval Date : 2018. 03.23.
KR Approval Date : 2018. 08.29.
USA Approval Date: 2018. 08.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.26.




HepatoCellular Carcinoma (HCC). UnRe-
sectable. TREAT.: Sorafenib Tablets.
"Primary" Cancer.
USA Approval Date: 2005. 12.20.
(*) Company : Bayer.
Patent : Expired.
TradeMark: Nexavar.
Web-Site : www.nexavar-us.com
UpDate: 2018. 10.15.




Metastatic ColoRectal Cancer (mCRC)
Liver. Irinotecan Eluting Embolic Beads.
RadioOpaque.
TransArterial ChemoEmbolisation (TACE)
Enabling Real-Time Visible, Lasting
Confirmation of Bead Location during &
Post-Embolisation
Visible Imaging>Computed Tomography
>Cone-Beam Computed
Tomography
>Fluoroscopy
CA Approval Date: 2016. 08.25.
CA Launch Date: 2016. 12.05.
EU Approval Date: 2017. 03.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.23.




Metastatic ColoRectal Cancer (mCRC)
Liver. Selective Internal RadioTherapy
(SIRT). Y-90 Glass Microspheres.
TransArterial RadioEmbolisation (TARE).
CA Approval Year: 2002.
EU Approval Date: ?
HK Launch Date: ?
KR Launch Date: 2016. 01.26.
MY Launch Date: 2016. 10.19.
SG Launch Date: 2015. 06.11.
(*) Company : BTG Intl.
Patent : Expired
TradeMark: TheraSphere
Web-Site : www.btgplc.com
UpDate: 2018. 10.24.




Metastatic ColoRectal Cancer (mCRC) Liver. Selective Internal RadioTherapy (SIRT). Y-90 Resin Microspheres.
TransArterial RadioEmbolisation (TARE)
- Approved in AR, AU, BR, CH, EU, IL,
IN, SG, TK & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.16.




Metastatic Melanoma (Skin) Liver UnRe-
sectable. TREAT.: Melphalan.HCl inj.
Delivery: Percutaneous Hepatic Perfusion
AU Approval Date: 2012. 11.05. (2nd Gen)
EU Approval Date: 2012. 04.05. (2nd Gen)
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 10.15.




Surgical Resection>4X Bipolar Resection Device.
EU CE Mark.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.15.


>LIVER CANCER. *'s products
This section has no products